Gilead to acquire Pharmasset for $11 billion
Gilead Sciences Inc. plans to buy Pharmasset Inc. in a cash deal valued at about $11 billion Gilead said Monday that the acquisition will accelerate the development of an all-oral regimen for the treatment of the chronic hepatitis C virus (HCV). The companies said the combination also will